Phastar published a case study detailing how the company designed a Bayesian Phase I/II trial for an emerging biotech preparing for its first-in-human oncology study to support dose escalation, early efficacy assessment, and regulatory acceptance from both the FDA and EMA.
Published
Signal category
Research & Knowledge
Quote
“In our latest case study, we share how Phastar designed a Bayesian Phase I/II trial that supported dose escalation, early efficacy assessment, and regulatory acceptance from both the FDA and EMA.”
— Sam Caley|Phastar team
Company
Phastar
Bringing data to life
- Industry
- Biotechnology Research
- Location
- London, GB
- Company size
- 374 employees
Phastar is an award-winning specialist biometrics and data science CRO, trusted by pharma, biotech, and medical device companies worldwide. With a global team of data specialists, it brings expertise, precision, and pace to every trial – because behind every data point is a patient waiting for treatment. Phastar doesn’t just deliver high-quality clinical trial data. It partners with clients to turn complexity into clarity. Leveraging technology, AI-enhanced analytics, advanced statistical methods, and deep therapeutic expertise, it accelerates regulatory approvals, ensures compliance with global standards and mitigates risk. Phastar has a proven track record in transforming complex data into clear, actionable intelligence, empowering its partners to accelerate drug development. With scalable, tailored solutions, it expedites trials – bringing life-changing therapies to patients faster.
Founded 2007